Scopus Biopharma Inc. (SCPS): Price and Financial Metrics


Scopus Biopharma Inc. (SCPS): $0.38

-0.01 (-2.91%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add SCPS to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

SCPS Stock Price Chart Interactive Chart >

Price chart for SCPS

SCPS Price/Volume Stats

Current price $0.38 52-week high $8.03
Prev. close $0.39 52-week low $0.36
Day low $0.37 Volume 76,100
Day high $0.41 Avg. volume 227,835
50-day MA $0.57 Dividend yield N/A
200-day MA $2.20 Market Cap 8.02M

Scopus Biopharma Inc. (SCPS) Company Bio


Scopus BioPharma Inc. develops therapeutics drugs targeting the endocannabinoid system. The company was formerly known as Project18 Inc. and changed its name to Scopus BioPharma Inc. in December, 2017. The company was incorporated in 2017 and is based in New York, New York.


SCPS Latest News Stream


Event/Time News Detail
Loading, please wait...

SCPS Latest Social Stream


Loading social stream, please wait...

View Full SCPS Social Stream

Latest SCPS News From Around the Web

Below are the latest news stories about Scopus BioPharma Inc that investors may wish to consider to help them evaluate SCPS as an investment opportunity.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

Good morning!

William White on InvestorPlace | February 18, 2022

Scopus BioPharma Provides Update Following Annual Meeting of Stockholders

Overwhelming Majority of Shares Voted by Unaffiliated Stockholderswere in Favor of Scopus' Director Nominees Lasters’ Ownership Position and Annual Meeting Results are being Challenged in Court Company Believes Ultimate Outcome of Annual Meeting Will Depend on Results of Pending Cases NEW YORK, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: SCPS) (“Scopus” or the “Company”) today announced that it has filed an amendment to the Current Report on Form 8-K that was filed by the Co

Yahoo | January 10, 2022

DR. MORRIS C. LASTER WINS PROXY CONTEST AS STOCKHOLDERS ELECT HIS NOMINEES TO SCOPUS BIOPHARMA INC. BOARD OF DIRECTORS

Dr. Morris C. Laster ("Dr. Laster"), who, together with other proxy participants, beneficially owns 6,006,000 shares of common stock, par value $0.001, of Scopus BioPharma Inc. (Nasdaq: SCPS) ("Scopus" or the "Company"), announced today that stockholders of the Company have elected Dr. Laster's two director nominees, Mordechai Saar Hacham and Joshua Levine to the Company's Board of Directors at the Company's 2021 Annual Meeting of Stockholders (the "Annual Meeting").

Yahoo | January 6, 2022

Scopus BioPharma Issues Open Letter to Stockholders Detailing Morris Laster’s Campaign Against the Company

Latest Legal Claims by Laster Actually Call into Question his Stock Ownership Company Urges Stockholders to Vote “FOR ALL” of the Company’s Director Nominees on the WHITE Proxy Card NEW YORK, Dec. 17, 2021 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: “SCPS”) today issued a second letter to its stockholders in connection with the Company’s Annual Meeting of Stockholders (the “Annual Meeting”) that will be reconvened on Monday, December 20, 2021 at 11:30 a.m., Eastern time. The record date f

Yahoo | December 17, 2021

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

We've reached the halfway point of the week and there's no slowing down as we dive into the biggest pre-market stock movers for Wednesday!

William White on InvestorPlace | December 8, 2021

Read More 'SCPS' Stories Here

SCPS Price Returns

1-mo -25.46%
3-mo -45.62%
6-mo -85.21%
1-year -94.63%
3-year N/A
5-year N/A
YTD -76.76%
2021 -88.98%
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.5981 seconds.